DiaMedica Therapeutics Inc DMAC

Healthcare Biotechnology

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

NDAQ:DMAC - Post by User

DiaMedica Therapeutics Inc

Bullboard Posts

Comment by joelouon Dec 07, 2018 9:24pm

62 Views

Post# 29085852

RE:RE:RE:RE:RE:RE:RE:RE:RE:DMA On Watch Territory

“Yeah, if I had an extra $5000 I might do the same but I have had too many companies screw me like this one just did so I have no cash left. It would be nice if some day one or two of them would actually turn around and push the price up.”

I hear ya!

Now let us remember that DMAC needs to maintain the $2 minimum on the Nasdaq... wouldn’t that be a shame if they dropped below this threshold!!

Bullboard Posts

The top 10 Canadian medical stocks